You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Powerful Efficacy

Virologically Suppressed Patients

TANGO Logo
TANGO Logo

TANGO Study Design

Confidence with Powerful Efficacy Maintained at Week 96 in Virologically Suppressed Patients

NON-INFERIORITY MAINTAINED WITH NO INCREASED RISK OF VIROLOGICAL FAILURE⁴
NA
Tango

ITT-E Snapshot analysis. 

Adapted from van Wyk et al, 2020² 

48-week primary endpoint (HIV-1 RNA ≥50 copies/mL): DOVATO 0.3% (1/369) vs TAF-containing regimens 0.5% (2/372)³

Virology – a closer look 

Viral Blips

Slide deck showing the viral blip results from the TANGO Phase clinical trials at 48-weeks

Robust Virological Control Compared to TAF-Containing Regimens

  • Occurrences of Viral Blips* were low and Comparable Across Arms Through Week-48⁴
  • Proportion of patients with viral blips was similar across both arms at Week-48: 2% (9/369) in DOVATO vs 5% (18/372) in TAF-containing regimens.⁴
  • Dr. Jean van Wyk, Global Medical Lead for Dolutegravir at ViiV Healthcare, discusses results from the TANGO 48-week sub-analysis evaluating intermittent viremia.

* A viral blip is a transient increase in viral load ≥50 copies/mL to <200 copies/mL bounded by viral loads <50 copies/mL. Note: individual patients could have had ≥ 1 blip.

Dovato Efficacy Beyond Standard Clinical Endpoints 

Target Detected / Target Not Detected results from TANGO Phase III clinical trial

Slide deck showing the TANGO TD/TND results at 48-weeks

Expert Reactions
Tango 96 Week Data

References:

  1. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. Doi:10.1093/cid/ciz1243.
  2. van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.
  3. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
  4. Wang R, Horton J, Wright J, et al. Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study. Presented at: 17ᵗʰ European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Poster PE 3/15.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: October 2021 PM-IE-DLL-WCNT-200018